ReviewAnnals of medicine2026
The role of mesencephalic astrocyte-derived neurotrophic factor in digestive diseases.
Review in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMesencephalic astrocyte-derived neurotrophic factor (MANF) is an evolutionarily conserved endoplasmic reticulum (ER)-resident and secreted protein highly expressed in the digestive system. Emerging evidence has highlighted its pivotal roles in liver diseases, as well as in other digestive diseases including intestinal and pancreatic disorders. This review summarizes the expression, molecular mechanisms, and pathological roles of MANF in digestive diseases and evaluates its translational potential as a therapeutic target and biomarker. DISCUSSION: MANF exerts effects primarily through ER stress regulation, antioxidative responses, and regulation of inflammatory signaling cascades. In liver diseases, MANF plays a context-dependent dual roles. It protects against alcohol-associated liver disease (ALD), metabolic dysfunction-associated steatotic liver disease (MASLD), hepatocellular carcinoma (HCC), drug-induced liver injury (DILI), and ischemia/reperfusion injury, yet promotes immune tolerance in chronic hepatitis B virus (HBV) infection and acts as an oncogenic driver in intrahepatic cholangiocarcinoma (ICC). In pancreatic disorders, MANF protects β-cells from ER stress-induced apoptosis in diabetes and mitigates acute pancreatitis. In intestinal diseases, it ameliorates inflammatory bowel disease (IBD) and necrotizing enterocolitis (NEC). The function of MANF are determined by cellular context, disease stage, and specific microenvironmental signals.
conclusionMANF emerges as a key regulator of digestive tract homeostasis. Targeting MANF may represent a potential therapeutic strategy for preventing and treating digestive diseases. Its dynamic expression patterns also suggest possible biomarker utility. Further studies are needed to optimize targeted interventions and validate its clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.